Gornati Laura, Zanoni Ivan, Granucci Francesca
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.
Division of Gastroenterology, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States.
Front Immunol. 2018 Jun 27;9:1484. doi: 10.3389/fimmu.2018.01484. eCollection 2018.
Vaccines represent the discovery of utmost importance for global health, due to both prophylactic action to prevent infections and therapeutic intervention in neoplastic diseases. Despite this, current vaccination strategies need to be refined to successfully generate robust protective antigen-specific memory immune responses. To address this issue, one possibility is to exploit the high efficiency of dendritic cells (DCs) as antigen-presenting cells for T cell priming. DCs functional plasticity allows shaping the outcome of immune responses to achieve the required type of immunity. Therefore, the choice of adjuvants to guide and sustain DCs maturation, the design of multifaceted vehicles, and the choice of surface molecules to specifically target DCs represent the key issues currently explored in both preclinical and clinical settings. Here, we review advances in DCs-based vaccination approaches, which exploit direct DCs targeting and activation options. We also discuss the recent findings for efficient antitumor DCs-based vaccinations and combination strategies to reduce the immune tolerance promoted by the tumor microenvironment.
疫苗对全球健康而言是极其重要的发现,这既归因于其预防感染的预防作用,也归因于其对肿瘤疾病的治疗干预。尽管如此,当前的疫苗接种策略仍需完善,以成功产生强大的保护性抗原特异性记忆免疫反应。为解决这一问题,一种可能性是利用树突状细胞(DC)作为抗原呈递细胞启动T细胞的高效性。DC的功能可塑性能够塑造免疫反应的结果,以实现所需的免疫类型。因此,选择指导和维持DC成熟的佐剂、设计多方面的载体以及选择特异性靶向DC的表面分子,是目前临床前和临床环境中探索的关键问题。在此,我们综述了基于DC的疫苗接种方法的进展,这些方法利用了直接靶向和激活DC的选项。我们还讨论了基于DC的高效抗肿瘤疫苗接种的最新发现以及减少肿瘤微环境促进的免疫耐受的联合策略。